Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Common therapeutic indications Common adverse effects Different pharmacokinetics and potency Different chemical families Common mechanism of action (cyclooxygenase inhibition) Different selectivities to COX I and II Similarities more striking than Differences
NSAID
Loss of PGI2 induced inhibition of LTB4 mediated endothelial adhesion and activation of neutrophils
Leukocyte-Endothelial Interactions
Mucosal Ulceration
Aspirin
GI system
1. Dose dependent hepatitis 2. Reyes syndrome
Metabolic
1. Uncoupling of Oxid. Phosphorylation 2. Hyperglycemia and depletion of muscle and hepatic glycogen Endocrine: corticosteroids, thyroid
Other NSAIDs
Phenylbutazone: additional uricosuric effect. Aplastic anemia. Indomethacin: Common ADRs. CNS most common: halucinations, depression, seizures Propionic acids: better tolerated. Differ in pharmacokinetics Acetaminophen: differes in effects and ADRs from rest. Main toxicity: hepatitis due to toxic intermediate which depletes glutathione. Treat with N-acetylcysteine.
Rofecoxib Naproxen
RR: 0.38 (0.25, 0.57) RR: 0.43* (0.24, 0.78)
5 4 3 2 1
p < 0.001.
Rofecoxib N=4047
45 (1.7) 28 (1.0) 11 (0.4) 6 (0.2)
Naproxen N=4029
19 (0.7) 10 (0.4) 8 (0.3) 1 (0.04)
Single Dose Rx
Two Weeks Rx
80
40 0
* **
Placebo Celecoxib Ibuprofen N=7 400 mg 800 mg N=7 N=7
80
40 0 Placebo N=12
** **
Rofecoxib Indomethacin 50 mg QD 50 mg TID N=12 N=10
Proc. Natl. Acad Sci. USA 1999;96:272-277. J. Pharmacol. Exp. Ther. 1999;289:735-741.
Investigator-Reported Thrombotic Cardiovascular Events in the VIGOR Study Compared with Phase IIb/III OA Study
3.5 Cumulative Incidence %
3.0
2.5 2.0
1.5
1.0 0.5
Naproxen (VIGOR)
0.0
0 2 4 6 8 10 Months of Follow-up 12 14
FDA files
Treatment of Gout